- Home
- HERE vs SLN Comparison
HERE vs SLN Comparison
Compare HERE & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HERE
- SLN
- Stock Information
- Founded
- HERE 2019
- SLN 1994
- Country
- HERE China
- SLN United Kingdom
- Employees
- HERE N/A
- SLN N/A
- Industry
- HERE Other Consumer Services
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- HERE Real Estate
- SLN Health Care
- Exchange
- HERE Nasdaq
- SLN Nasdaq
- Market Cap
- HERE 296.4M
- SLN 345.3M
- IPO Year
- HERE 2023
- SLN N/A
- Fundamental
- Price
- HERE $5.28
- SLN $6.70
- Analyst Decision
- HERE
- SLN Buy
- Analyst Count
- HERE 0
- SLN 6
- Target Price
- HERE N/A
- SLN $39.67
- AVG Volume (30 Days)
- HERE 247.8K
- SLN 194.5K
- Earning Date
- HERE 11-28-2025
- SLN 11-06-2025
- Dividend Yield
- HERE N/A
- SLN N/A
- EPS Growth
- HERE N/A
- SLN N/A
- EPS
- HERE 0.91
- SLN N/A
- Revenue
- HERE $380,467,350.00
- SLN $25,830,000.00
- Revenue This Year
- HERE N/A
- SLN N/A
- Revenue Next Year
- HERE N/A
- SLN N/A
- P/E Ratio
- HERE $5.85
- SLN N/A
- Revenue Growth
- HERE N/A
- SLN 40.39
- 52 Week Low
- HERE $1.60
- SLN $1.97
- 52 Week High
- HERE $15.64
- SLN $12.80
- Technical
- Relative Strength Index (RSI)
- HERE N/A
- SLN 53.16
- Support Level
- HERE N/A
- SLN $6.59
- Resistance Level
- HERE N/A
- SLN $7.00
- Average True Range (ATR)
- HERE 0.00
- SLN 0.52
- MACD
- HERE 0.00
- SLN -0.06
- Stochastic Oscillator
- HERE 0.00
- SLN 56.60
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.